Uterine Cancer Therapeutics & Diagnostics Market Trends

Statistics for the 2023 & 2024 Uterine Cancer Therapeutics & Diagnostics market trends, created by Mordor Intelligence™ Industry Reports. Uterine Cancer Therapeutics & Diagnostics trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of Uterine Cancer Therapeutics & Diagnostics Industry

This section covers the major market trends shaping the Uterine Cancer Therapeutics & Diagnostics Market according to our research experts:

Endometrial Adenocarcinoma to Witness Highest Growth Over the Forecast Period

Growing burden of endometrial adenocarcinoma is expected to drive the Uterine Cancer Therapeutics & Diagnostics Market in this segment. According to the Cancer.gov, an endometrial adenosarcoma is the most common type of cancer which is found in women and about 80 percent of uterine cancers are adenocarcinomas, and vary in degree of severity.

Increasing obesity among women is considered as the prime factor responsible for the growing incidence of the endometrium carcinoma as around 90% of the uterine cancers affect the endometrium. with the growing incidence of the disease and the rising awareness about the same, it is believed that rapid growth of the segment will occur in the coming future.

Incidence Rate per 100,000 Individuals of Uterine Cancer in Women, United Kingdom, by Age, 2015 - 2017

North America is Expected to Dominate the Market over the Forecast Period

North America region is believed to dominate the Global Uterine Cancer Therapeutics and Diagnostics Market in the near future. The prime reason for the growth of the market in this region is the rising incidence of the disease and the growing awareness among the general population. American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, around 10% of uterine body cancers are sarcoma. In addition, rapid technological advancements in the diagnostics and faster adoption to new technologies in the country are provoking the overall growth of the market studied.

Uterine Cancer Therapeutics & Diagnostics Market - Growth Rate by Region

Uterine Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)